Bob Tribe joined the Therapeutic Goods Administration (TGA), Australia in 1971 as a GMP inspector after having worked in the pharmaceutical industry in a senior Quality Assurance position. He became Chief GMP Inspector in 1980, a position he held until his retirement in 2004. While at TGA he was elected Chairman of PIC/S in 2000-2001.
After retiring from TGA he established “Bob Tribe Consulting” and has assisted many GMP regulatory authorities around the world reach the PIC/S level of regulatory control. Of the sixteen regulatory authorities that he has assisted to date, ten have obtained PIC/S membership. He also consults to pharmaceutical manufacturers wishing to achieve compliance with PIC/S GMP requirements.
Bob is a member of the WHO Expert Committee on Specifications for Pharmaceutical Preparations and undertakes GMP inspections for the WHO under its Pre-qualification Programme.
Bob is the ISPE Regulatory Affairs Advisor for the Asia-Pacific region.
The 2025 ISPE Singapore Conference and Exhibition, hosted by the ISPE Singapore Affiliate, took place 27–29 August at Suntech Singapore. It is one of the largest and most well-regarded events for...
This year, the ISPE Singapore Affiliate proudly marks 25 years of advancing pharmaceutical engineering and technology. It has played a pivotal role in shaping the pharmaceutical and biopharmaceutical industries in the region, fostering a strong community focused on education, collaboration, and innovation. As we reach this remarkable milestone, we reflect on the journey and look ahead to an...
The Pharmaceutical Inspection Co-operation Scheme (PIC/S) celebrated its 50th anniversary at a special symposium in Dublin, Ireland on 4 October 2022. Since the first meeting of the PIC Committee in 1972, PIC/S has come a long way! The symposium was titled “Thriving at 50 and Striving Forward” and was aimed at promoting and...
On 17 August 2022, four international regulators discussed how the Covid-19 pandemic had taught regulators to look for alternative ways of doing GMP inspections and also to rely more on each other to make determinations on the GMP status of manufacturers of medicines.
At the ISPE Singapore Conference on 17 August 2022 during an online panel discussion, four international regulators discussed how the Covid-19 pandemic had taught regulators to look for alternative ways of conducting GMP inspections and also to rely more on each other to make determinations on the GMP status of manufacturers of medicines.